Left plot: odds ratio (95% CI) in females and males in each trialĮFigure 5. Effects of corticosteroids on 28-day mortality according to sex. Effects of corticosteroids on 28-day mortality according to whether patients were aged ≤60 or >60 years at the time of randomizationĮFigure 4. Effects of corticosteroids on 28-day mortality according to whether patients received vasoactive medication at the time of randomizationĮFigure 3. Effects of corticosteroids on 28-day mortality according to whether patients received invasive mechanical ventilation (IMV) at the time of randomizationĮFigure 2. Summary of assessments of the risk of bias in the estimated effect of corticosteroids on mortality in the METCOVID trialĮFigure 1. Characteristics of patients included in the METCOVID trialĮTable 4. Characteristics of the METCOVID trialĮTable 3. Summary of assessments of the risk of bias in the estimated effect of corticosteroids on mortality and serious adverse events in each trial, with brief explanation of judgementsĮTable 2. Lists of investigators and steering committeeĮTable 1. The prespecified primary analysis was the fixed-effect analysis, which should be used to guide clinical interpretation of the results.
![citing comprehensive meta analysis 3.3 calculations citing comprehensive meta analysis 3.3 calculations](https://www.mdpi.com/ijerph/ijerph-16-02735/article_deploy/html/images/ijerph-16-02735-g001-550.jpg)
The 95% CI for the average effect (shown here) is wide because there is a small number of studies, some of which have very small sample size.
![citing comprehensive meta analysis 3.3 calculations citing comprehensive meta analysis 3.3 calculations](https://www.meta-analysis.com/Images/content/screenshots/correlations_2.gif)
Citing comprehensive meta analysis 3.3 calculations trial#
CAPE COVID indicates Community-Acquired Pneumonia: Evaluation of Corticosteroids in Coronavirus Disease CoDEX, COVID-19 Dexamethasone COVID STEROID, Hydrocortisone for COVID-19 and Severe Hypoxia DEXA-COVID 19, Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 REMAP-CAP, Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia Steroids-SARI, Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure.ĪThe random-effects analysis estimates both the average and variability of effects across studies. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial result is for patients who were receiving invasive mechanical ventilation at randomization.
![citing comprehensive meta analysis 3.3 calculations citing comprehensive meta analysis 3.3 calculations](https://www.mdpi.com/nutrients/nutrients-10-00601/article_deploy/html/images/nutrients-10-00601-g001-550.jpg)
The area of the data marker for each trial is proportional to its weight in the fixed-effect meta-analysis.